Intellia headquarters (Kyle LaHucik for Endpoints News)
June 11, 2023 08:30 AM EDTUpdated June 13, 07:50 PM
R&D

In­tel­lia’s sec­ond CRISPR ther­a­py re­duces swelling at­tacks by 95% in hered­i­tary an­gioede­ma

Ryan Cross

Senior Science Correspondent

An ex­per­i­men­tal CRISPR ther­a­py has dra­mat­i­cal­ly low­ered lev­els of an in­flam­ma­tion-pro­mot­ing pro­tein and re­duced bouts of harm­ful swelling by 95% in pa­tients with an in­her­it­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Pfiz­er CEO says op­por­tu­ni­ties with Trump ‘clear­ly out­weigh’ the risks for phar­ma

Will CRISPR mat­ter?

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times